IDEXX officer Mazelsky proposes $17.7M share sale
The notice lists an aggregate market value of $17,678,196.60; the shares came from an issuer stock-option exercise paid in cash.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
IDEXX Laboratories, Inc. officer and director Jonathan Jay Mazelsky reported a proposed sale of 25,140 common shares, with an approximate sale date of November 4, 2026. The securities information lists an aggregate market value of $17,678,196.60. The shares were acquired from the issuer through a stock option exercise on November 4, 2026, with cash payment.
Key Figures
Key Terms
Rule 144 regulatory
Stock Option Exercise financial
Securities To Be Sold regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.